Mutant-type p53 (mt p53) is largely accumulated in cancer cells due to its increased stability. To elucidate the mechanism of mt p53 stabilization, we analysed the turnover of p53 mutated at codon 248 whose alteration is most frequently found in human cancers. Proteasome inhibition induced the accumulation of ubiquitinated mt p53, indicating that the ubiquitinated forms were essentially unstable and degraded by the proteasome. The presence of a small amount of the ubiquitinated mt p53 relative to the abundant non-ubiquitinated form suggested that the mt p53 ubiquitination was a ratelimiting process in the slow turnover. Two phenomena destabilizing mt p53 via the ubiquitin-proteasome degradation were proved to be independent. First, the coexpression of wild-type p53 (wt p53) promoted mt p53 destabilization as feedback regulation. Second, geldanamycin also induced mt p53 destabilization through the dissociation of the protein from hsp90 but not through the restoration of wt p53 function. Neither the mutantspeci®c conformation nor the N-terminal phosphorylation seemed to contribute directly to the mt p53 stabilization. Further, a two-dimensional gel electrophoresis revealed that most of the post-translationally modi®ed mt p53 was equally subjected to ubiquitination and subsequent proteasomal degradation. These ®ndings are evidence that mt p53 stabilization depends on the impaired ubiquitination due to both the loss of wt p53 function and the hsp90 association.
Introduction
Tumor suppressor p53 is a regulatory protein that determines the cell regulation in response to DNA damage and other cellular stresses (Hartwell et al., 1994; Hall et al., 1996; Harris, 1996) . The posttranslational control, especially the turnover of p53 protein, is known to play an important role in the adjustment of its function. Wild-type p53 (wt p53) is normally a very short-lived protein, with a less than 30 min half-life, and it can barely be detected in normal cells. Under DNA damage and other stimulations, however, the wt p53 level rapidly increases in the cell and this increased level is required for the functioning of p53 as a guardian of the genome (Kastan et al., 1991; Fritsche et al., 1993) . This accumulation of p53 occurs largely due to the stabilization rather than to the increased synthesis of p53, and the stability is thought to be regulated through a ubiquitin-proteasome proteolytic pathway (Ciechanover et al., 1991; Schener et al., 1993; Chowdary et al., 1994; Maki et al., 1996) .
The p53 gene is altered in more than half of all human cancers (Soussi et al., 1996) . Importantly, the majority of mutant-type p53 (mt p53) in tumor cells is usually detected at high levels, and the mutant proteins have much longer half-lives (more than 24 h) regardless of the presence of environmental stimuli to the cells . Most mt p53 proteins not only lose their suppressor function but also can gain a new capacity for promoting cell growth (Dittmer et al., 1993) . Biochemical analyses demonstrated that mt p53 can abolish the function of wt p53 by interacting through the oligomer formation, known as a dominant negative function (Milner et al., 1991) . Thus, the stabilization of mt p53 is signi®cant considering the process of tumor formation and the therapeutic strategies such as gene therapy against a variety of human malignancies (Roth et al., 1997) .
The mechanisms underlying the mt p53 stabilization are not yet understood (Blagosklonny, 1997; Brown et al., 1997; Save et al., 1998) . The mdm2 protein, whose gene is transactivated by p53, was recently reported to promote proteasomal degradation of wt p53 as negative feedback regulation Haupt et al., 1997) . Accordingly, mt p53 losing wt p53 function is unlikely to induce mdm2, and the absence of the feedback regulation is thought to induce the accumulation of mt p53. Indeed, mdm2 was found to destabilize mt p53 proteins when overexpressed in cultured cells Haupt et al., 1997) . However, the feedback regulation by mdm2 alone does not always determine the mt p53 levels. Certain cancer cells contained high levels of wt p53 and mt p53 even in the presence of mdm2 overexpression (Landers et al., 1997; Cordon-Cardo et al., 1994) , and some studies using antisense oligonucleotides targeted for mdm2 showed no increase of p53 protein (Kondo et al., 1995; Chen et al., 1998) . Thus, this feedback regulation model needs to be evaluated more comprehensively by considering the involvement of not only mdm2 but also other p53-induced proteins.
There are other potential mechanisms aecting the mt p53 stabilization. One is the modi®cation by protein phosphorylation and dephosphorylation (Steegenga et al., 1996) . Shieh et al. (1997) reported that DNA damage-induced phosphorylation at the N-terminal serine 15 of p53 attenuates the interaction of the protein with mdm2, which leads to the stabilization of p53. However, the N-terminal phosphorylation status of mt p53 has not yet been determined so far. Another factor which may account for mt p53 stabilization is a mutant-speci®c protein conformation. Although missense mutations in cancers occur at several dierent codons, most mt p53 proteins obtain a commonly mutated conformation which is reactive to an anti-p53 monoclonal antibody, Pab240 (Gannon et al., 1990;  a b c d
Stabilization of the mutant-type p53 Y Nagata et al Cho et al., 1994) . Previous works indicated that conformations of mt p53 were related to the susceptibility to degradation in the presence of human papilloma virus E6 oncoprotein (Medcalf et al., 1993) . Further, geldanamycin (GA), an antibiotic of the benzoquinone ansamycin class, was reported to destabilize mt p53 protein, but not wt p53 (Blagosklonny et al., 1995) . Although the precise mechanism of mt p53 destabilization induced by GA remains unclear, the latest observation that GA disrupted the interactions of mt p53 with heat shock protein hsp90 shed light on the connection of mt p53 stability to the chaperone association (Whitesell et al., 1998) .
In the present study, we focused on understanding the whole mechanism of mt p53 turnover and its stabilization. Our data demonstrated that the impaired ubiquitination of mt p53 leads to the stabilization of the protein, due to the two independent mechanisms; the loss of wt p53 function and the hsp90 association. Neither a mutant-speci®c conformation nor phosphorylation of the mt p53 was demonstrated to contribute directly to the stabilization of mt p53.
Results
Mutant p53 is accumulated due to its increased stability in Saos-2 cells
The majority of the p53 mutations occur in the core domain which contains the DNA binding activity of the protein (residues 102 ± 292), and the mutations result in the loss of DNA contact followed by the transcriptional activation of regulatory genes. In the present study, we examined the turnover of p53 protein which was mutated at codon 248 from Arg to Trp (R248W) because the missense mutation at this residue is most frequently observed in human cancers . We developed a Saos-2 osteosarcoma cell line (originally p53 null) permae Figure 1 Polyubiquitination of mutant-types p53 in Saos-2 and U251-MG cells. (a) Increased stability of mutant-type p53(R248W) in Saos-2 cells. A Western blot analysis using the anti-p53 antibody DO-1 revealed that the treatment with a protein synthesis inhibitor, cycloheximide (CHX) (10 mg/ml), for 4 and 12 h little aected the level of a mutant-type (mt) p53 (R248W) (lanes 2 and 3, respectively) compared with the amount of mt p53 in the untreated cells (lane 1). Original Saos-2 cells showed no p53 expression (lane 4). (b) High molecular bands of mt p53 induced by proteasome inhibition. Membrane-permeable speci®c protease inhibitors were applied to mt p53(R248W)/Saos-2 cells for 6 h. A Western blot analysis using the antibody DO-1 showed that the treatment with the proteasome inhibitor MG132 (10 mM) produced ladder bands of mt p53 (indicated by triangles in lane 2), while E64d (10 mM), a calpain inhibitor (10 mM) and chloroquine (100 mM) each had no eect on the condition of mt p53 (lanes 3 ± 5, respectively), compared with that in the untreated cells (lane 1). The bands for b-actin showed that equal amounts of proteins were loaded in all lanes. (c) Accumulation of polyubiquitinated mt p53 under proteasome inhibition. The p53(R248W)/Saos-2 cells were transiently transfected with a pCGN-Ub vector expressing HA-tagged ubiquitin (HA-Ub) in the presence or absence of MG132. The immunoprecipitates with the anti-p53 antibody Pab1801 (P) and with control IgG (N) were detected by an anti-HA monoclonal antibody. The high molecular bands as indicated by a star were mt p53 proteins conjugated with HA-Ubs and endogenous ubiquitins only in the cells treated with MG132 (lane 1). Positive (+) and negative (7) indicate the presence and absence, respectively, of mt p53 expression, HA-Ub, and MG132. Ig indicates non-speci®c backgrounds by immunoglobulins. (d) Ubiquitination of the Met tyrosine kinase receptor. p53(R248W)/Saos-2 cells were transiently transfected with a pCGN-Ub vector in the presence or absence of MG132. Met was then immunoprecipitated with an anti-Met polyclonal antibody, and the immunoprecipitate was electrophoresed and detected by the anti-HA antibody. MG132 treatment induced polyubiquitinated Met detected as high molecular bands (lane 2, indicated by a star). Polyubiquitinated Met was not remarkably detected in MG132-untreated cells (lane 3). The precipitates obtained by using control IgG contained no high molecular p53 (lane 1) in the presence of MG132. A Western blot analysis using the same cell lysates indicated an increased amount of Met in the presence of MG132 (lanes 4) compared with that in the absence of MG132 (lane 5). (e) Ubiquitination of endogenous mt p53 (R273H) in the U251-MG glioma cell line. The CHX treatment did not change the amount of the p53 (lane 2), and high molecular bands of the p53 were detected in the presence of MG132 (as indicated by a triangle in lane 3), but not in the untreated cells (lane 1). The ubiquitination of the p53 was analysed by expressing HA-Ub followed by immunoprecipitation with Pab1801, as described above. The accumulation of polyubiquitinated mt p53 was found in the presence of MG132 (as indicated by a star in lane 4), but not in the absence of MG132 (lane 5). The immunoprecipitation with control IgG in the presence (lane 6) and absence (lane 7) of MG132 showed no high molecular p53
Stabilization of the mutant-type p53 Y Nagata et al nently expressing mt p53(R248W), and we named the cell line p53(R248W)/Saos-2. To demonstrate the stabilization of p53(R248W) in Saos-2 cells, a Western blot analysis using the cells treated with a protein synthesis inhibitor, cycloheximide (CHX) (10 mg/ml), was performed by using the anti-p53 monoclonal antibody DO-1 (Figure 1a) . The treatment for 4 and 12 h had little eect on the mt p53 level (Figure 1a, lanes 2 and 3, respectively) , compared with the amount of mt p53 in the untreated cells ( Figure 1a, lane 1) . Thus, p53(R248W) in Saos-2 cells accumulated due to the protein stabilization but not to the increased synthesis and was a suitable model for the analysis of mt p53 stabilized in many cancer cells .
Mutant p53 is spontaneously degraded through a ubiquitin-proteasome pathway
To evaluate the proteolytic system of mt p53, we used membrane-permeable speci®c protease inhibitors on the p53(R248W)/Saos-2 cells for 6 h. A Western blot analysis was performed using the DO-1 antibody ( Figure 1b) . The use of a proteasome inhibitor (MG132) (10 mM) revealed ladder bands of mt p53 that increased by about 7 ± 8 kDa each ( Figure 1b , lane 2), suggesting that these bands were ubiquitinated forms of mt p53 which were targeted for proteasomal degradation (Hochstrasser, 1996; Coux et al., 1996; Pagano, 1997) . In contrast, the cysteine protease inhibitor E64d, a calpain inhibitor (carbobenzoxylleucinyl-leucinal) and the lysosome inhibitor chloroquine each had no eect on the condition of mt p53 (Figure 1b , lanes 3 ± 5, respectively), as shown similarly in the untreated cells (Figure 1b, lane 1) .
To con®rm the intracellular ubiquitination of mt p53, p53(R248W)/Saos-2 cells were transiently transfected with a pCGN-Ub vector driving the expression of hemagglutinin (HA)-tagged ubiquitin (HA-Ub), in the presence or absence of MG132. The p53 protein was then immunoprecipitated with the monoclonal antibody Pab1801 which reacts to the N-terminal amino acids 32 ± 79 of both mt p53 and wt p53 proteins, and the immunoprecipitate was electrophoresed and detected by an anti-HA monoclonal antibody. As shown in Figure 1c , high molecular bands were polyubiquitinated mt p53 proteins which were thought to be conjugated with both endogenous ubiquitins and HA-Ubs, in the cells treated with MG132 ( Figure 1c (Figure 1c, lanes 4 and 5) . Moreover, the appearance of polyubiquitinated mt p53 under the conditions of proteasome inhibition indicated that the ubiquitination of mt p53 is a degradation signal directed to proteasome. Thus, ubiquitinated mt p53 is thought to be a normally unstable intermediate targeted for proteasomal degradation. The discrepancy in the molecular weights of ubiquitinated mt p53 between Figure 1b and 1c might be explained by a relatively low proportion of HA-Ub in polyubiquitin chains, resulting in the detection of higher molecular ubiquitinated p53 by the anti-HA antibody in the immunoprecipitates. Another explanation is an inaccessibility of the anti-p53 antibody to its epitope in multiple ubiquitinated p53 in the denatured condition, leading to the detection of lower ubiquitinated p53 by the anti-p53 antibody in the whole cell extracts. Similar results have been seen in previous reports of other proteins (Hiller et al., 1996; Musti et al., 1997) . To con®rm that our assay system is ecient for detecting ubiquitination of another substrate, we examined turnover of the Met tyrosine kinase receptor, which had been reported to be ubiquitinated and degraded through proteasome (Jeers et al., 1997) . p53(R248W)/ Saos-2 cells were transiently transfected with a pCGNUb vector in the presence or absence of MG132. Met was then immunoprecipitated with an anti-Met polyclonal antibody, and the immunoprecipitate was electrophoresed and detected by the anti-HA antibody. As shown in Figure 1d Mutant p53 has an impaired ubiquitinating process leading to its slow turnover Most substrates including wt p53 for a ubiquitinproteasome pathway are short-lived proteins (Hochstrasser, 1996) , but mt p53 protein is paradoxically stabilized. Some impaired process(es) in the mt p53 turnover are therefore suspected to exist. Generally, the proteolysis via a ubiquitin-proteasome pathway is represented by the following two processes: (a) the identi®cation of a substrate and its ubiquitination by ubiquitination machineries such as ubiquitin-protein ligases, and (b) the recognition of the ubiquitinated substrate and its digestion by the proteasome. If the process (a) is impaired in the mt p53 turnover, most mt p53 will accumulate in the cells without being ubiquitinated and the amount of ubiquitinated mt p53 will be much less than that of non-ubiquitinated form. If the process (b) is disordered, ubiquitinated mt p53 will be spontaneously accumulated due to its inability to enter the proteasome even without proteasome inhibition. From the results shown in Figure 1 , an abundant mt p53 accumulated mostly in the non-ubiquitinated form. Although the proteasome inhibition readily induced the appearance of ubiquitinated mt p53, the amount of non-ubiquitinated mt p53 remained unchanged. These ®ndings supported the idea that only a small portion of mt p53 is led to the ubiquitination process and that ubiquitinated mt p53 is essentially unstable because the proteasome can recognize and degrade it. Therefore, the ubiquitinating process rather than the proteasomal degradation is likely to be impaired in the mt p53 turnover.
The coexpression of wt p53 destabilizes mt p53 in Saos-2
We next investigated how the ubiquitination of mt p53 can be impaired in the cell. We initially examined whether the restoration of wt p53 function aects mt p53 stability. A two-dimensional (2-D) gel electrophoresis analysis was performed to distinguish between mt p53 and wt p53 on the gel (Figure 2a ). The p53(R248W)/Saos-2 and original Saos-2 cells which expressed wt p53 by Ad5CMV-p53 infection (10 p.f.u./ cell) were analysed separately ( Figure 2a , panels (a) and (d), respectively). Mt p53 and wt p53 proteins each displayed several distinct spots originating from posttranslationally modi®ed isoforms. In accord with a previous report, isoforms of wt p53 revealed a slightly faster mobility and a more acidic distribution, compared with those of mt p53 (Ullrich et al., 1992) . Then, wt p53 was coexpressed in p53(R248W)/Saos-2 cells, and the cells at 24 and 48 h after the infection were subjected to the 2-D gel electrophoresis analysis (Figure 2a, panels (b) and (c), respectively). The levels of both wt and mt p53 isoforms decreased at 48 h. The MG132 treatment for 6 h prior to the harvest at 48 h after the infection inhibited the degradation of both wt and mt p53 isoforms (Figure 2a, panel (e) ). Further, the Western blot analysis using the same cell lysates revealed a marked induction of mdm2 in the cells at 48 h after the infection (Figure 2c , lane 2), while mdm2 was hardly detected in uninfected p53(R248W)/Saos-2 cells (Figure 2c , lane 1). These results indicated that wt p53 function including mdm2 transactivation stimulated the proteasomal degradation of mt p53, suggesting that mt p53 was stabilized due to the loss of wt p53 function.
Geldanamycin induces the destabilization of mt p53 in Saos-2
To analyse the mt p53 destabilization by GA, p53(R248W)/Saos-2 cells were cultured in the absence or presence of GA (2 mM) for 6 h ( Figure 2b ). The GA treatment decreased the amount of mt p53 ( Figure 2b , lane 2), and the utilization of CHX in combination with GA enhanced the decrease of mt p53 (Figure 2b , lane 3), indicating that GA induced the rapid turnover of mt p53. In addition, the use of the combination of MG132 and GA resulted in the appearance of ubiquitinated forms (Figure 2b , lane 4). We next examined the eect of GA on wt p53 expression in Ad5CMV-p53-infected Saos-2 cells. The treatment of GA made little dierence in the p53 state (Figure 2b , lane 7), compared with the result in the absence of GA (Figure 2b, lane 6 ). This ®nding demonstrated that GA treatment selectively destabilized mt p53 and not wt p53 in Saos-2 cells through the ubiquitin-proteasome system.
Wt p53 function and geldanamycin destabilize mt p53 independently
Our data demonstrated that both the restoration of wt p53 function and the GA treatment promoted the proteasomal degradation of mt p53 in p53(R248W)/ Saos-2 cells. One possible explanation for the mt p53-speci®c eect of GA is that this agent might make mt p53 transactivate target genes of wt p53. To test this possibility, we investigated whether mdm2 is expressed in the cells treated with GA for 6 h ( Figure 2c, lane 4) . The lack of mdm2 induction suggested that GA destabilizes mt p53 without the restoration of the wt p53 function. Further, the addition of GA to the wt p53-expressing p53(R248W)/Saos-2 cells promoted the mt p53 destabilization more rapidly than wt p53 expression alone did (Figure 2a, panel(f) in comparison with the data in Figure 2a , panel(c)). In the condition shown in panel(f) in Figure 2a , the induction of mdm2 was not further augmented ( Figure 2c , lane 3). Collectively, these ®ndings indicated that GA treatment speci®cally destabilized mt p53 independent of a negative feedback regulation by wt p53 function.
GA disrupts the complex formation between mt p53 and hsp90 in Saos-2
The heat shock protein hsp90 is involved in achieving the conformation of many regulatory proteins including transcription factors and protein kinases (Pratt et al., 1997) . GA is known to inhibit hsp90 by its binding selectively to the chaperone (Prodromou et al., 1997; Stebbins et al., 1997) . Since a previous study revealed that mt p53 binds to hsp90 in a cell type-dependent manner (Whitesell et al., 1998) , we examined the interaction between mt p53 and hsp90 in p53(R248W)/Saos-2 cells. We treated cells with or without GA for 10 min and immunoprecipitated the mt p53 in cell lysates containing 10 mM molybdate (Whitesell et al., 1998) , by using the antibody Pab1801. The Western blot analysis of the immunoprecipitates using an anti-hsp90 antibody showed that hsp90 was coprecipitated with mt p53 (Figure 3 , lane 2), and that GA treatment disrupted this physical binding ( Figure  3, lane 3) . A similar experiment was done with wt p53 in Saos-2 cells expressed by Ad5CMV-p53 in the absence of GA (Figure 3, lane 1) , and the result that hsp90 was not coprecipitated with wt p53 emphasized the speci®c interaction between mt p53 and hsp90. Thus, mt p53 in Saos-2 showed a complex formation with hsp90, and this complex was disrupted by GA treatment.
Hsp90 is associated with the impairment of mt p53 ubiquitination
We have demonstrated two concurrent GA-induced eects on mt p53 in Saos-2. One is the dissociation between hsp90 and mt p53. Another is the destabiliza- The p53(R248W)/Saos-2 and original Saos-2 cells which express wt p53 by Ad5CMV-p53 (10 p.f.u./cell) were analysed separately (panels a and d, respectively). Mt p53 and wt p53 proteins each displayed several distinct spots, and isoforms of wt p53 (indicated by a star) revealed a slightly faster mobility and a more acidic distribution compared with those of mt p53. Then, wt p53 was coexpressed in p53(R248W)/Saos-2 cells, and the cells at 24 and 48 h after the infection were subjected to the 2-D gel electrophoresis analysis (panels b and c, respectively). The levels of both wt and mt p53 isoforms were found to decrease at 48 h. The MG132 treatment for 6 h prior to the harvest at 48 h after the infection inhibited the degradation of both wt and mt p53 (panel e). The treatment of geldanamycin (GA) for 6 h prior to the harvest at 48 h after the infection promoted only mt p53 destabilization more rapidly than wt p53 expression alone did (panel f). The bactin showed that similar amounts of protein were loaded on the gels. (b) The eect of geldanamycin on mutant-and wildtypes p53 in Saos-2 cells. p53(R248W)/Saos-2 cells cultured in the absence (lane 1) or presence (lanes 2 ± 4) of GA (2 mM) for 6 h were examined in a Western blot analysis using the antibody DO-1. The GA treatment decreased the amount of mt p53 (lane 2), and CHX in combination with GA enhanced the decrease of mt p53 Figure 2a, panel (a) ). The induction of mdm2 was not further augmented by the addition of GA to the wt p53-expressing p53(R248W)/Saos-2 cells (lane3, corresponding to Figure 2a, panel (f) ). The treatment with GA for 12 h resulted in no mdm2 induction (lane 4, corresponding to lane 2 in Figure 2b ). The use of luciferase-and b-galactosidase-expressing adenoviruses as a control did not aect the p53 status, and most cells in this assay were estimated to be eectively infected with these adenoviral vectors (data not shown). (Miyake et al., 1998) . PAGE; polyacrylamide gel electrophoresis, IEF; isoelectric focusing Stabilization of the mutant-type p53 Y Nagata et al tion of mt p53. Therefore, we speculated that hsp90 could be involved in the impairment of mt p53 ubiquitination. To con®rm this hypothesis, we ®rst examined whether ubiquitination process in the turnover of mt p53 is actually facilitated after mt p53 is released from hsp90. We studied the eciency of the mt p53 ubiquitination in Saos-2 under the GA treatment. p53(R248W)/Saos-2 cells were incubated with GA for 5 or 10 min and GA was washed out immediately. Then, proteasomal degradation was inhibited by MG132 treatment for 1 h to estimate the formation of ubiquitinated mt p53. In the presence of MG132, ubiquitinated mt p53 was more accumulated in Saos-2 cells treated with GA for 5 and 10 min (Figure 4a , lanes 4 and 6, respectively), compared with that in GA-untreated cells (Figure 4a, lane 2) . Thus, GA treatment was shown to promote ubiquitinating process in mt p53 destabilization in Saos-2 cells. We next tested whether GA-induced destabilization of mt p53 is really due to the dysfunction of hsp90 by utilizing the transformation suppressing agent, radicicol. This agent is a macrocyclic anti-fungal antibiotic which is structurally very dissimilar from geldanamycin and has been reported to target hsp90 by binding to a distinct site(s) of this chaperone (Sharma et al., 1998) . To analyse the eect on mt p53 turnover by radicicol, p53(R248W)/Saos-2 cells were cultured in the absence or presence of radicicol (10 mM) for 6 h ( Figure 4b ). As expected, radicicol decreased the level of mt p53 ( Figure 4b, lane 2) . The use of MG132 inhibited the degradation of mt p53 by radicicol, resulting in the accumulation of high molecular mt p53 (Figure 4b , lane 3). Thus, radicicol, as well as GA, induced the rapid turnover of mt p53 and, to be noticed, radicicol seemed to have somewhat stronger eect on mt p53 than GA did (Figure 2b ). To make sure that the radicicol treatment also promoted the ubiquitination process of mt p53, the p53(R248W)/Saos-2 cells were transfected with pCGN-Ub to express HA-Ub and were treated with MG132 in the presence or absence of radicicol. The p53 protein immunoprecipitated with Pab1801 was separately detected using the anti-HA and anti-p53 antibodies. Increased polyubiquitination of mt p53 was demonstrated in the cells treated with radicicol by the anti-HA antibody (Figure 4c, lane 1) . In addition, the polyubiquitinated p53 was detected to some extent by the DO-1 antibody, suggesting that ubiquitination of p53, not of other proteins, was enhanced by radicicol (Figure 4c, lane 3) . Collectively, we concluded that hsp90 is associated with the impairment of ubiquitinating process of mt p53.
Mt p53 with Pab240-reactive conformation can be processed via a ubiquitin-proteasome pathway Most mutant-type p53 have a mutant-speci®c conformation reactive to the anti-p53 antibody Pab240 (Gannon et al., 1990) , and our present ®ndings indicated that mt p53 can associate with hsp90 selectively and be destabilized through the dissociation from hsp90 under GA treatment. In addition, a previous study showed that hsp90 was required for the achievement and/or stabilization of the Pab240-reactive conformation of mt p53 (Blagosklonny et al., 1996) . These ®ndings prompted us to investigate whether a Pab240-reactive conformation itself is advantageous to the mt p53 stabilization in p53(R248W)/Saos-2 cells. First, we examined the conformations of wt p53 and mt p53 in Saos-2 cells, using the reactivity of a structure-independent and a structure-dependent antibodies (Pab1801 and Pab240, respectively). As shown in Figure 5a , immunoprecipitation with Pab1801 showed bands for both wt p53 and mt p53 (Figure 5a , lanes 1 and 2, respectively), while Figure 3 The disruption of a physical association between mt p53 and hsp90 in Saos-2 cells by geldanamycin. The p53(R248W)/ Saos-2 cells were treated with or without GA for 10 min, and the mt p53 in cell lysates containing 10 mM molybdate was immunoprecipitated with antibody Pab1801. Using an anti-hsp90 antibody, a Western blot analysis of the immunoprecipitates showed that hsp90 was coprecipitated with mt p53 (lane 2), and that GA treatment disrupted this physical binding (lane 3). In contrast, hsp90 was not coprecipitated with wt p53 in Saos-2 cells even in the absence of GA (lane 1). The immunoprecipitation with control IgG in GA-untreated p53(R248W)/Saos-2 cells showed no band for hsp90 (lane 4). The cell lysates corresponding to lanes 1 ± 3 contained similarly abundant hsp90 (lanes 5 ± 7, respectively) and p53 (lanes 8 ± 10, respectively) mt p53 but not wt p53 was precipitated with Pab240 ( Figure 5a, lanes 4 and 3, respectively) . Further, we developed a new polyclonal antibody against the amino acids 131 ± 156 of human p53 (termed ap53-deg), since the region containing its epitope is rich in hydrophobic amino acid residues and is expected to be located most interiorly in the structure of wt p53 (Soussi et al., 1996) . The use of this antibody for immunoprecipitation revealed a speci®c band for mt p53 but not for wt p53 (Figure 5a, lanes 6 and 5, respectively) . Thus, the mt p53 was found to have a typical mutant-speci®c conformation which abnormally exposed the hydrophobic region critical for DNA binding.
Next, we studied the dynamics of mt p53 with this mutant-speci®c conformation. The p53(R248W)/Saos-2 cells were transfected with pCGN-Ub to express HAUb, in the presence or absence of MG132. The p53 protein was then immunoprecipitated with Pab240, and a b c Figure 4 The involvement of hsp90 in the impaired ubiquitination of mutant-type p53. (a) Increased ubiquitination of mt p53 by GA treatment. p53(R248W)/Saos-2 cells were incubated with GA for 5 (lanes 3 and 4) or 10 min (lanes 5 and 6) and GA was washed out immediately. Then, the cells were untreated (lanes 1,3, and 5) or treated (lanes 2,4, and 6) with MG132 for 1 h, and a Western blot analysis was done using the DO-1 antibody. In the presence of MG132, ubiquitinated mt p53 (as indicated by triangles) was more accumulated in GA-treated Saos-2 cells (lanes 4 and 6) compared with that in GA-untreated cells (lane 2). (b) Mt p53 destabilization induced by radicicol. p53(R248W)/Saos-2 cells were cultured in the absence or presence of radicicol (10 mM) for 6 h, and a Western blot analysis was done using the DO-1 antibody. Radicicol rapidly decreased the level of mt p53 (lane 2), compared with that in untreated cells (lane 1). The combination of MG132 and radicicol induced the accumulation of ubiquitinated mt p53 (lane 3). The use of MG132 alone had less eect on mt p53 (lane 4). (c) The p53(R248W)/Saos-2 cells were transfected with pCGN-Ub vector and were treated for 12 h with MG132 in the presence (lanes 1 and 3) or absence (lanes 2 and 4) of radicicol. The p53 protein immunoprecipitated with Pab1801 was separately detected using the anti-HA and anti-p53 antibodies. Increased polyubiquitination of mt p53 was demonstrated in the cells treated with radicicol by the anti-HA antibody (lane 1). In addition, the polyubiquitinated p53 was detected to some extent by the DO-1 antibody, suggesting that ubiquitination of p53, not of other proteins, was enhanced by radicicol (lane 3, as indicated by stars)
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Y Nagata et al detected using an anti-HA antibody (Figure 5b) . Polyubiquitinated mt p53 was demonstrated in the cells treated with MG132 ( Figure 5b , lane 1), but not in the untreated cells ( Figure 5b, lane 2) . Thus, mt p53 with a Pab240-reactive conformation was processed via a ubiquitin-proteasome pathway, suggesting that such a mutant-speci®c conformation itself did not contribute directly to the stabilization of the protein.
Phosphorylation of mt p53 little aects the stabilization
Finally, we examined the possibility of another mechanism resulting in the mt p53 stabilization, a post-translational modi®cation of mt p53 by the protein phosphorylation. Indeed, p53 is well-known to be regulated by multiple phosphorylation (Steegenga et al., 1996) . The phosphorylation of wt p53 at serine 15 was recently reported to contribute to the stabilization of the protein in response to DNA damage (Shieh et al., 1997) . If mt p53 in cancer cells is constitutively phosphorylated at this site through a dysregulated phosphorylation, the protein will accumulate in the cells. First, we analysed the phosphorylation status of mt p53 in p53(R248W)/Saos-2 cells, by using an antibody directed against an epitope spanning phosphorylated serine 15 (ap53-P-Ser-15) ( Figure 6 ) (Shieh et al., 1997) . U2OS cells were used as a control because they are known to express wt p53 that rapidly responds to the treatment with g-irradiation. A Western blot analysis using the antibody DO-1 showed the level of p53 in cell lysates from unstimulated U2OS, irradiated U2OS, and p53(R248W)/Saos-2 cells (Figure 6, lanes 1 ± 3,  respectively) . The amount of wt p53 was slightly increased in irradiated U2OS cells ( Figure 6 , lane 2), compared with that in unstimulated cells (Figure 6 , lane 1). The same amount of cell lysates was blotted onto another membrane (Figure 6 , lanes 4 ± 6, corresponding to lanes 1 ± 3, respectively). The ap53-P-Ser-15 antibody reacted strongly with phosphorya b Figure 5 Polyubiquitin conjugation of mutant-type p53 with a mutant-speci®c conformation reactive to Pab240. (a) The conformation of wt p53 and mt p53(R248W) in Saos-2 cells was examined using the reactivity of a structure-independent (Pab1801) antibody and a structure-dependent (Pab240) antibody. Immunoprecipitation with Pab1801 showed bands for both wt and mt p53 (lanes 1 and 2, respectively), while mt p53, but not wt p53, was precipitated with Pab240 (lanes 4 and 3, respectively) . The use of a newly developed polyclonal antibody against the amino acids 131 ± 156 within the hydrophobic region of human p53 (termed ap53-deg) also precipitated a speci®c band for mt p53 but not for wt p53 (lanes 6 and 5, respectively). A Western blot analysis was done using HRP-conjugated DO-1 antibody to reduce the background bands of immunoglobulins. (b) The p53(R248W)/Saos-2 cells were transfected with pCGN-Ub to express HA-Ub, in the presence or absence of MG132. Mt p53 was immunoprecipitated with Pab240, and detected using an anti-HA antibody. Polyubiquitinated mt p53 as indicated by a star was demonstrated in the cells treated with MG132 (lane 1), but not in untreated cells (lane 2). The precipitates obtained by using control IgG contained no high molecular p53 (lane 3) in the presence of MG132 lated wt p53 in irradiated U2OS (Figure 6, lane 5) , and to a low extent with that in unstimulated U2OS cells (Figure 6, lane 4) . The mt p53 at serine 15 was only slightly phosphorylated ( Figure 6 , lane 6), compared with the result from wt p53 in irradiated U2OS cells. This indicated that abnormal phosphorylation at serine 15 was not responsible for the mt p53 stabilization in intact cells.
Second, we investigated the dynamics of the ubiquitination of mt p53 under MG132 treatment, using a 2-D gel electrophoresis analysis (Figure 7) . As shown in Figure 2a , mt p53 was found to be several distinct spots due to post-translational modi®cations. Previous studies showed that these charge dierences of these isoforms on 2-D gel electrophoresis re¯ected distinct phosphorylation states (Ullrich et al., 1992; Selkirk et al., 1994) . The mt p53 was analysed using the antibody DO-1 in the absence or presence of MG132 (Figure 7a and b, respectively) , with a long exposure of the ®lm to detect spots for the ubiquitinated forms. The accumulation of high molecular spots originating from most isoforms was detected under MG132 treatment. These additional spots were thought to be ubiquitinated forms because they appeared only under proteasome inhibition and increased by about 7 ± 8 kDa each. This ®nding suggested that most isoforms of mt p53 in intact cells equally proceed to the ubiquitin-proteasome pathway. Thus, the ubiquitination and degradation machineries accepted all of the posttranslationally-modi®ed mt p53 isoforms regardless of both the mutant-speci®c conformation and the phosphorylation pattern of the protein.
Discussion
In the present study, we made a thorough investigation of the mechanisms underlying the stabilization of mt p53. A ubiquitin-proteasome proteolytic system is implicated in the degradation of mt p53 as well as that of wt p53. However, the turnover of these two proteins varies; the turnover of wt p53 is fast, while mt p53 proteins are stabilized in intact cells. The wt p53 under DNA damage and other cellular stresses is stabilized, at least in part, by the repression of mdm2-mediated negative feedback through the N-terminal phosphorylation of p53, and this mechanism was not applicable to the stabilization of mt p53 proteins. In cancer cells, non-ubiquitinated mt p53 accumulated rather than ubiquitinated mt p53. Treatment with MG132 induced the appearance of ubiquitinated forms of the protein targeted for the proteasome degradation but it did not markedly aect the level of mt p53 itself. On the basis of our observations, we surmise that the Figure 6 The status of mutant-type p53 phosphorylation at serine 15 in Saos-2 cells. The phosphorylation status of mt p53(R248W) in Saos-2 cells was analysed by using an antibody directed against an epitope spanning phosphorylated serine 15 (ap53-P-Ser-15). U2OS cells with and without g-irradiation treatment were used as a control. A Western blot analysis using the antibody DO-1 showed the level of p53 in cell lysates from unstimulated U2OS, irradiated U2OS, and p53(R248W)/Saos-2 cells (lanes 1 ± 3, respectively). The level of p53 in irradiated U2OS increased slightly (lane 2). The same amount of cell lysates was blotted onto another membrane (lanes 4 ± 6, corresponding to lanes 1 ± 3, respectively). The a p53-P-Ser-15 antibody reacted strongly with phosphorylated wt p53 in irradiated U2OS (lane 5), and to a low extent with that in unstimulated U2OS cells (lane 4). The mt p53 at serine 15 in Saos-2 was only slightly phosphorylated (lane 6) Figure 7 Most of the isoforms mutant-type p53 in Saos-2 cells equally proceed to a ubiquitin-proteasome pathway. The mt p53(R248W) cells were examined by 2-D gel electrophoresis analysis using the antibody DO-1 in the absence and presence of MG132 (a and (b), respectively). The spots for the ubiquitinated isoforms were detected with a long exposure of the ®lm. The accumulation of high molecular spots originating from most isoforms was found under MG132 treatment, as indicated by a star (b) proteasome normally recognizes and degrades polyubiquitinated mt p53 and that the ubiquitinating processes of mt p53 is impaired resulting in a small amount of ubiquitinated forms relative to abundant non-ubiquitinated form. In eukaryotic cells, the covalent conjugation of ubiquitins is believed to be mostly used as a signal for substrate recognition by the proteasome (Coux et al., 1996; Hochstrasser, 1996) . The present ®ndings that mt p53-expressing cells were full of the protein with no ubiquitin conjugations, and that polyubiquitinated mt p53 was readily recognized and degraded by proteasome, suggested insucient interactions between mt p53 and ubiquitinating machineries such as ubiquitin-protein ligases. Another possibility is that the deubiquitination of a ubiquitin fusion catalyzed by deubiquitinases occurs excessively, resulting in the changes from polyubiquitinated to nonubiquitinated mt p53. However, abnormal regulation in ubiquitination and deubiquitination systems is unlikely because of the presence of polyubiquitinated mt p53 under the conditions of proteasome inhibition. Therefore, we concluded that mt p53 acquired the stabilization through impaired ubiquitination, probably due to mt p53-speci®c properties which dier from those of wt p53.
To further elucidate the mechanism for mt p53 stabilization, we investigated how the stability of the protein can be disrupted experimentally. First, we demonstrated that the expression of wt p53 destabilized mt p53 in Saos-2 cells. Our data suggested that p53-induced proteins other than mdm2, such as p21, a cyclin-dependent kinase inhibitor which was simultaneously transactivated by wt p53 (data not shown), did not interfere with the wt p53-induced destabilization of mt p53. Therefore, our ®ndings are direct evidence that mt p53 is stabilized by the loss of wt p53 function.
Next, we demonstrated that hsp90 inhibitors with dierent properties, GA and radicicol, destabilized mt p53 in Saos-2 through the ubiquitination and proteasomal degradation. The observation that both agents showed the destabilizing eect on mt p53 in Saos-2 convinced us of the involvement of hsp90 in the mt p53 stabilization. If hsp90 is responsible for the spontaneous stabilization of mt p53, the chaperone would block the ubiquitination process which was demonstrated to be mainly impaired in mt p53 degradation pathway. Indeed, either GA or radicicol treatment enhanced the accumulation of ubiquitinated mt p53 under the situations where proteasome was inhibited. These results showed that hsp90 is associated with the impaired ubiquitination of mt p53. To be sure, mt p53 but not wt p53 can make a complex with hsp90 in Saos-2 cells, which was disrupted by the treatment of GA (and radicicol, data not shown). As shown in Figures 3 and 4a , both the dissociation from hsp90 and the subsequent ubiquitination of mt p53 occurred simultaneously after the GA treatment. This ®nding supported the idea that the association of mt p53 with hsp90 blocks the ubiquitination process.
Further, we concluded that the involvement of hsp90 in mt p53 stabilization is independent of the loss of feedback regulation by wt p53 function. The reasons for the independence are: (1) mt p53, but not wt p53, speci®cally associated with hsp90; (2) GA selectively destabilized mt p53, but not wt p53, in the same cellular environment; (3) GA did not induce the mdm2 expression that is usually associated with wt p53 expression, and (4) GA accelerated the wt p53-induced destabilization of mt p53 (panel (f) in Figure 3a) .
Why does mt p53 preferentially bind to chaperone hsp90? One possible explanation is based on the ®ndings that mt p53 shows a mutant-speci®c conformation, especially exposing the region rich in hydrophobic residues that is found structurally in the interior of wt p53 (Gannon et al., 1990; Legros et al., 1994; Vojtesek et al., 1995) . In fact, our ap53-deg antibody against the epitope within the hydrophobic cluster reacted with mt p53 but not wt p53. Such hydrophobic residues on the surface of the protein could be selectively recognized as an incompletely folded or unfolded molecule by molecular chaperones such as hsp90 (Wiech et al., 1992; Miyata et al., 1992) . Mutated p53 itself might be essentially unstable and acquire a high anity to hsp90. Indeed, Pab240-reactive mt p53 was found to be normally ubiquitinated and degraded by the proteasome. A previous report suggested the possibility that hsp90 would be involved in the mt p53 stabilization by assisting the mutant to achieve the Pab240-reactive conformation (Blagosklonny et al., 1996) . Our ®nding may exclude this model and supported the idea that ubiquitination machineries such as ubiquitin-protein ligases might hardly interact with mt p53 which is trapped by hsp90. This condition is thought to lead to the accumulation of ubiquitin-unconjugated mt p53 in the cell.
Taken together, the above observations indicated that two independent mechanisms exist for the stabilization of mt p53 within the same cellular environment: the loss of feedback regulation by wt p53 function, and the hsp90 association. These mechanisms result in the disturbance of the mt p53 ubiquitination. Our ®ndings are important for understanding the molecular mechanisms of mt p53 stabilization in tumor formation and those of the selective ubiquitin-mediated proteasomal proteolysis of p53.
Materials and methods

Cell cultures
The osteosarcoma cell line Saos-2 and malignant glioma cell line U251-MG were cultured in RPMI1640 (Gibco ± BRL, Rockville, MD, USA) supplemented with 10% (v/v) heatinactivated fetal calf serum (FCS) (Bio-Whittaker, Walkersville, MD, USA). The osteosarcoma cell line U2OS was cultured in Dulbecco's modi®ed Eagle's medium (DMEM) (Gibco ± BRL) supplemented with 10% (v/v) FCS. The girradiation of U2OS cells was carried out at a dose of 10 Gy, and the cells were cultured for 6 h for the assay. Each medium contained 100 units/ml penicillin and 100 mg/ml streptomycin sulfate. The p53(R248W)/Saos-2 cells were cultured in a medium containing G418 and hygromycin (each 0.2 mg/ml) additionally for the selection of transfected cells. All cell lines were incubated in a humidi®ed CO 2 incubator at 378C.
Antibodies and reagents
Anti-p53 monoclonal antibodies (Pab1801, Pab240, and DO-1) were obtained from Oncogene Science (Uniondale, NY, USA); anti-b-actin monoclonal antibody (AC-15), from Sigma (St. Louis, MO, USA); anti-HA monoclonal antibody (12CA5), from Boehringer Mannheim (Mannheim, Germany). Horse radish peroxidase (HRP)-conjugated DO-1, anti-Met polyclonal antibody (C-28) and anti-mdm2 monoclonal antibody (SMP14), were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-hsp90 monoclonal antibody (16F1) was purchased from StressGen Biotechnologies (Vancouver, British Columbia, Canada). The polyclonal antibody to p53 phosphorylated at serine 15 (ap53-P-Ser-15 antibody) was described elsewhere (Shieh et al., 1997) . MG132 (carbobenzoxyl-leucinyl-leucinyl-leucinal, CBZ-LLLal) and a calpain inhibitor (carbobenzoxyl-leucinylleucinal) were supplied by Peptide Institute (Osaka, Japan); chloroquine, from Wako Inc. (Osaka, Japan); E64d, cycloheximide, geldanamycin, radicicol and sodium molybdate were purchased from Sigma.
Generation of ap53-deg antibody
The antiserum was raised by the subcutaneous immunization of rabbits with a chemically synthesized, KLH-conjugated NKMFCQLAKTCPVQWVDSTPPPGTR (amino acids 131 ± 156 of p53). The antiserum was further anity purified on a column containing the peptide cross-linked sepharose.
p53 expression plasmid and permanent transfection into Saos-2 pSEp53(R248W), a plasmid coding human mutant p53(R248W), was constructed as follows: the NcoI ± XbaI fragment containing the full length of human mutant p53(R248W) cDNA was isolated from plasmid 248Trp (Aoyama et al., 1992) and ligated into the HindIII ± XbaI site of an expression vector, pAGE208, using HindIII ± NcoI adapter. The expression vector pAGE208 is a derivative of pAGE107 (Miyaji et al., 1990) , in which a G418 resistance gene was replaced with a hygromycin resistance gene. Saos-2 cells were transfected with a plasmid, p53RE8luc2, driving a luciferase expression under eight copies of p53-responsive elements and the minimum promoter from SV40 early region. Stable transformants of the plasmid were selected with 0.2 mg/ml of G418. Then the cells were double-transfected with pSEp53(R248W) and selected with 0.2 mg/ml of Hygromycin to stably express human mutant p53(R248W). These cells were named p53(R248W)/Saos-2 and they showed no clonal variations. The mt p53 showed no transactivation activity of the luciferase.
Adenovirus vectors
Replication-de®cient recombinant adenovirus vectors described previously (Miyake et al., 1998) were used in this study; Ad5CMV-p53, Ad5CMV-Luc and AxCALacZ expressed human wt-p53, control luciferase and b-galactosidase, respectively, driven by human cytomegalovirus immediate early promoter. Adenoviruses were propagated in the transformed human embryonal kidney cell line 293, which readily permits the replication of these E1 replicationde®cient adenoviruses. The viral titration was performed using a plaque (Miyake et al., 1998) . The Saos-2 cells were infected with these adenovirus vectors (10 p.f.u./cell) in RPMI1640 medium supplemented with 10% FCS. Cells were harvested at 24 h after the infection unless otherwise indicated.
Electrophoresis analysis
Western blot analysis was described elsewhere (Miyake et al., 1998) . For the two-dimensional gel electrophoresis, cells were lysed in an isoelectric focusing buer (9.5 M urea, 2% NP-40, 2% pharmalytes (pH 5 ± 8) (Pharmacia Biotech, Uppsala, Sweden), and 5% mercaptoethanol) and then sonicated twice for 5 s each time, and then centrifuged at 16 000 g for 30 min. The supernatants were isoelectrically focused at 500 V for 6 h. Proteins were then separated in the second dimension in 8% SDS polyacrylamide gels for the Western blot analysis using the antibody DO-1.
HA-tagged ubiquitin expression vector and transfection
Full-length human ubiquitin cDNA(228-bp) was ampli®ed by PCR from a prostate cDNA library by the forward primer (5' -CTAGTCTAGAATG CAGATCTTCGTGAAAACC -3') and the reverse primer (5'-CGAATCTAGATTAAC-CGCA-3') containing an XbaI site (underlined). Cycling reactions were performed for 30 cycles using pfu DNA polymerase (Stratagene, La Jolla, CA, USA). Each cycle consisted of denaturation at 948C for 1 min, annealing at 558C for 1 min and extension at 728C for 1 min. The PCR fragments were digested with XbaI and ligated into a pCGN expression vector (pCGN-Ub). To express hemagglutinin (HA) epitope-tagged ubiquitin, the vector was transfected into p53(R248W)/Saos-2 cells by the liposome-mediated gene transfer method (Felgner et al., 1987) .
Ubiquitination and chaperone binding assays
Cells were lysed in a buer (100 mM Tris-HCI (pH 8.0), 100 mM NaCl, 1% NP40, 3% aprotinin, 10 mg/ml leupeptin, 1.0 mM phenylmethylsulfonyl¯uoride) for the ubiquitination assay or in a buer containing molybdate (10 mM Tris-HCl (pH 7.4), 1 mM MgCl 2 , 0.2% Tween 20, 10 mM sodium molybdate, 3% aprotinin, 10 mg/ml leupeptin, 1.0 mM phenylmethylsulfonyl¯uoride) for the chaperone binding assay. The cell lysates were sonicated twice for 5 s each time. After centrifugation at 16 000 g for 20 min at 48C, the supernatant fraction (containing total amounts of proteins (2 mg) in a volume of 300 ml) was immunoprecipitated with an appropriate antibody for 48C for 1 h, followed by an addition of Protein G Plus/Protein A-agarose (30 ml) (Oncogene Science) for 1 h. After being washed ®ve times in a lysis buer on ice and extracted into an SDS sample buer at 958C for 3 min, the immunoprecipitates were then resolved by SDS ± PAGE on a 10 ± 20% gradient gel, transferred to a nitrocellulose membrane, and examined by the ECL detection system.
